Single Dose Dry Powder Inhaler for COPD and Asthma
8/11/16 Diseases like chronic pulmonary obstructive disease (COPD) and asthma are on the rise, which is boosting revenues and opportunities for companies with micro component experience in this field. The markets for these drugs and inhalers are projected to grow rapidly over the next decade as the incidence of COPD and other diseases increases. A recent report from Transparency Market Research forecasts that the global market for generic inhalation and nasal spray drugs will jump from $21.8 billion in 2014 to $35.5 billion by 2023.
Most people with COPD and asthma use oral inhalers that contain two drugs that compliment the therapeutic actions of one another. Micro Engineering Solutions has excellent experience in the area of inhaler technology and they have the exclusive worldwide rights to sell one of the most innovative DPIs available today, the DoseOne™ Single Dose Powder Inhaler.
Development of the DoseOne™ single dose powder inhaler (US Patent #7,832,399 B2 and #8,360,057 B2) required a multi-disciplinary team approach, as any such drug delivery device needs to combine not just design skills, but also software and mechanical engineering capabilities, and expertise in analytical science and industrialisation. MES worked on the DoseOne™ device from concept creation, allowing the design to be sympathetic to the requirements for mass manufacture and regulatory compliance.
The DoseOne™ is equipped with a simple dose readiness indicator and a dose delivery indicator — which means it conforms with strict FDA patient-compliance regulations previously only attained by expensive MDIs and multi-use DPIs.
DoseOne™ is a perfect example of what can be achieved if an innate understanding of micro manufacturing design and manufacturing is combined with an understanding of the regulatory environment that exists around drug delivery devices these days, and a realisation of the potential for innovative solutions that cater for mass “self” administration of drugs in a cost effective and safe way.
If you are a pharma manufacturer out there looking to locate a novel, cost-effective, and efficient drug delivery option, please email Donna Bibber at donna@microengineeringsolutions.com. For full details of DoseOne™ see www.dose-one.com
‹‹Back